Boehringer Ingelheim Press Release

01/03/2018 - 04:01 Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M
12/19/2017 - 02:55 Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
12/18/2017 - 04:34 Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders
12/15/2017 - 04:26 Change in the Board of Managing Directors at Boehringer Ingelheim
12/11/2017 - 08:48 Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
11/20/2017 - 04:59 Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential
11/08/2017 - 03:12 Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
11/02/2017 - 06:45 Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
10/30/2017 - 04:00 Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
09/29/2017 - 10:46 Boehringer Ingelheim and FEI partner to promote equine health and education
09/28/2017 - 08:07 Boehringer Ingelheim joins forces with partners around the world towards the elimination of rabies
09/18/2017 - 05:29 BOEHRINGER INGELHEIM HELPS HEALTH CARE PROFESSIONALS TO LISTEN FOR THE SOUNDS OF IPF
09/07/2017 - 10:28 Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments
09/07/2017 - 07:47 Boehringer Ingelheim is initiating Phase IIa study for the development of a new treatment for diabetic retinopathy a leading cause of vision-loss
08/24/2017 - 05:27 Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
08/03/2017 - 05:07 Next generation of veterinary scientists gathers at National Institutes of Health for National Veterinary Scholars Symposium
08/02/2017 - 02:12 Boehringer Ingelheim achieves good growth in the first half of 2017
07/23/2017 - 22:35 People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey
06/29/2017 - 01:23 'More than Systemic Sclerosis: The Inside Story' - patients reveal the unseen impact of lung fibrosis
06/08/2017 - 06:41 Boehringer Ingelheim builds Digital Lab BI X with focus on innovative digital solutions in healthcare
05/16/2017 - 05:29 Boehringer Ingelheim strengthens early science portfolio through comprehensive multifaceted partnership with Peking University
05/15/2017 - 22:18 Boehringer Ingelheim Inaugurates World-Class Biopharmaceutical Manufacturing Facility in China
05/10/2017 - 02:50 Boehringer Ingelheim Phase II trial now enrolling patients with the kidney disease Lupus Nephritis
04/05/2017 - 03:33 Boehringer Ingelheim: A New World Leader in Animal Health
04/05/2017 - 02:19 Successful financial year 2016 for Boehringer Ingelheim
03/30/2017 - 06:33 Novozymes and Boehringer Ingelheim announce Strategic Collaboration in Probiotics for Poultry Hatcheries
03/02/2017 - 04:02 Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers
03/02/2017 - 01:05 Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million
02/28/2017 - 00:47 New global survey results show: 2 out of 3 patients said they were involved in the decision-making process about the most appropriate treatment in IPF
02/15/2017 - 08:22 Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments
02/09/2017 - 04:52 Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung
01/01/2017 - 20:45 Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
11/28/2016 - 07:10 Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
11/14/2016 - 04:46 New analysis from the IntroDia survey reveals how people with type 2 diabetes are informed of their diagnosis
11/08/2016 - 02:23 New European study highlights differing priorities in physicians therapy goals when treating advanced lung cancer patients
10/26/2016 - 07:32 Most successful animal health vaccine of all time reaches milestone of two billion pigs being protected
10/21/2016 - 01:04 Three projects win 2016 European PRRS Research Award sponsored by Boehringer Ingelheim Animal Health
10/13/2016 - 00:13 Boehringer Ingelheim announces agreement with Ceva Sante Animale for the sale of certain Merial assets
10/08/2016 - 22:36 Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016
10/08/2016 - 22:31 Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016
09/29/2016 - 07:09 Boehringer Ingelheim and SARAH CANNON Research Institute launch strategic collaboration to develop novel immune-oncology therapies
09/28/2016 - 05:03 BOEHRINGER INGELHEIM BOOSTS IMMUNE-ONCOLOGY PIPELINE THROUGH COLLABORATION WITH VIRATHERAPEUTICS
09/26/2016 - 02:03 Preventing disease: One billion pigs vaccinated with Ingelvac PRRS MLV
09/01/2016 - 06:33 Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE immuno-oncology drug for multiple myeloma
08/28/2016 - 22:56 Saniona and Boehringer Ingelheim sign collaboration agreement in schizophrenia
08/03/2016 - 08:29 Boehringer Ingelheim: Growth in all core businesses
07/21/2016 - 06:46 CZ Veterinaria and Boehringer Ingelheim Animal Health announce cooperation to bring innovative sow vaccine Entericolix to the European market
07/20/2016 - 07:54 The European Stroke Organisation and Boehringer Ingelheim launch the Angels Initiative, a unique healthcare initiative to improve acute stroke care across Europe
07/14/2016 - 06:49 Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
07/13/2016 - 09:38 Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
07/07/2016 - 08:42 Marina von Keyserlingk and Daniel Weary win first Ruminant Well-being Award
07/04/2016 - 09:07 Gaia Novarino wins Boehringer Ingelheims FENS Award 2016 for Exceptional Research in Neuroscience
06/27/2016 - 02:59 Sanofi and Boehringer Ingelheim have reached definitive agreements to swap Sanofis Animal Health and Boehringer Ingelheims Consumer Healthcare businesses
06/10/2016 - 01:26 Simone Menne new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance
06/07/2016 - 08:55 Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
05/31/2016 - 08:59 Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
05/25/2016 - 08:37 Boehringer Ingelheim increases access to the medication for the treatment of HIV/Aids
05/24/2016 - 00:47 IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohns disease
05/23/2016 - 09:04 Pooled data analysis of placebo-controlled trials confirms improvement in quality of life within 4 weeks of using oral bisacodyl/sodium picosulfate
05/23/2016 - 08:56 Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
05/11/2016 - 07:16 Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
05/10/2016 - 08:45 New claim for use of Metacam 20mg/ml in sheep simultaneously granted in Australia, Canada and New Zealand
04/19/2016 - 06:45 Boehringer Ingelheim has a successful 2015 financial year
04/19/2016 - 01:23 Boehringer Ingelheim presented the 2015 results and an outlook for 2016 at the Annual Press Conference on 19 April 2016 in Ingelheim.
04/18/2016 - 06:43 New concept and design of boehringer-ingelheim.com: Corporate website as central web hub with customer-focused news and stories
04/08/2016 - 04:38 The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids
04/07/2016 - 07:34 Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung
04/04/2016 - 06:00 Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) in Emergency Situations
03/30/2016 - 05:18 Boehringer Ingelheim Venture Fund invests in Amal Therapeutics to develop novel therapeutic colorectal cancer vaccine
03/23/2016 - 12:39 Boehringer Ingelheim launches RE-COVERY DVT/PE: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa (dabigatran etexilate)
03/15/2016 - 07:04 2016 European PRRS Research Award: Boehringer Ingelheim Animal Health calls for submissions until
03/08/2016 - 08:58 New Analyses: Adding SPIRIVA Respimat Effective for Uncontrolled Asthma Regardless of Allergy Subtype 1,2,3
03/07/2016 - 08:38 AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
03/01/2016 - 04:41 Boehringer Ingelheim Animal Health supports independent PCV2 research with total of 650,000
02/29/2016 - 09:12 European Committee for Medicinal Products for Human Use recommends approval of Giotrif (afatinib) for advanced squamous cell cancer of the lung
02/29/2016 - 05:08 New survey gives voice to people living with a rare and devastating lung disease: When I think of IPF I think of breathlessness
02/25/2016 - 05:10 New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
02/10/2016 - 11:57 The European Society of Cardiology announces winners of innovative cardiovascular research grant programme
02/04/2016 - 11:20 SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
01/15/2016 - 11:04 World Association for Buiatrics and Boehringer Ingelheim Animal Health announce “Ruminant Well-being Award”
01/13/2016 - 15:21 Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia
12/22/2015 - 07:07 Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
12/21/2015 - 07:29 Boehringer Ingelheim 3 rd -generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
12/18/2015 - 09:12 Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
12/15/2015 - 11:58 Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
12/14/2015 - 11:01 Initiation of first multinational study to evaluate safety of OFEV ® (nintedanib) with add-on of pirfenidone in patients with IPF
12/07/2015 - 23:55 New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis
12/02/2015 - 02:36 Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer
11/29/2015 - 23:49 Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
11/26/2015 - 10:08 Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
11/16/2015 - 12:38 Boehringer Ingelheim named one of the most innovative companies worldwide
11/13/2015 - 12:59 New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
11/11/2015 - 12:30 Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs
11/10/2015 - 14:27 Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care
11/10/2015 - 12:36 Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
11/10/2015 - 06:57 Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
11/09/2015 - 19:14 New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
11/06/2015 - 19:01 EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015
11/06/2015 - 18:39 Change in Board of Managing Directors to ensure continuity and focus on the future
11/03/2015 - 05:03 Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound
Copy and paste this code to display this page on your website .
Syndicate content